The MAP1LC3A gene is located on chromosome 20 (20q11.22) in humans . It encodes a protein that is approximately 14 kDa in size and consists of 121 amino acids . The protein has two main isoforms resulting from alternative splicing . These isoforms can associate with either MAP1A or MAP1B, which are heavy chain subunits of the microtubule-associated proteins .
MAP1LC3A is a ubiquitin-like modifier involved in the formation of autophagosomal vacuoles (autophagosomes) . Autophagy is a cellular degradation process where cells recycle cytoplasmic contents, including damaged organelles and proteins, to maintain cellular homeostasis . LC3A is essential for the elongation of the phagophore membrane, a precursor to the autophagosome .
The protein also interacts with the reticulophagy receptor TEX264, which is involved in the remodeling of subdomains of the endoplasmic reticulum into autophagosomes upon nutrient stress . This interaction is crucial for the turnover of the endoplasmic reticulum through autophagy .
MAP1LC3A has been implicated in various diseases and conditions. For instance, its expression is suppressed in many tumor cell lines, suggesting a potential role in carcinogenesis . Additionally, diseases associated with MAP1LC3A include Cataract 13 with Adult I Phenotype and Diabetes Insipidus, Neurohypophyseal, X-Linked .
Human recombinant MAP1LC3A is widely used in research to study autophagy and related cellular processes. It serves as a marker for autophagosomes and is used in various assays to monitor autophagic activity . The protein’s role in autophagy makes it a valuable target for studying neurodegenerative diseases, cancer, and other conditions where autophagy plays a critical role .